Categories Earnings, Health Care

Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot

— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected.

— Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion.

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Review

— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.

— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.

— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.

— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

HOG Earnings: Key quarterly highlights from Harley-Davidson’s Q4 2022 financial results

Harley-Davidson, Inc. (NYSE: HOG) reported fourth quarter 2022 earnings results today. Revenue increased 12% year-over-year to $1.14 billion. Net income attributable to Harley-Davidson, Inc. rose 94% YoY to $42 million,

After positive Q4, Advanced Micro Devices (AMD) looks at a mixed 2023

Advanced Micro Devices, Inc. (NASDAQ: AMD) this week issued a cautious outlook for the first quarter of 2023, after reporting stronger-than-expected fourth-quarter results. The chipmaker did not provide full-year guidance,

META Earnings: All you need to know about Meta Platforms’ Q4 2022 earnings results

Meta Platforms, Inc. (NASDAQ: META) reported fourth quarter 2022 earnings results today. Revenue declined 4% year-over-year to $32.17 billion. Net income fell 55% to $4.6 billion while EPS dropped 52%

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top